1056016-18-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-C&R8 is used as a chiral ligand for the synthesis of enantiomerically pure compounds, which is essential for the development of pharmaceuticals with high selectivity and reduced side effects.
Used in Agrochemical Industry:
(R)-C&R8 is used as a catalyst in the production of agrochemicals, enabling the creation of enantiomerically pure active ingredients that can target pests more specifically and with less environmental impact.
Used in Fine Chemicals Industry:
(R)-C&R8 is utilized as a versatile catalyst in the synthesis of fine chemicals, contributing to the production of high-quality specialty chemicals with precise stereochemistry for various applications.
Used in Organic Synthesis:
(R)-C&R8 is used as a catalyst for asymmetric reactions, including the addition of organometallic reagents to carbonyl compounds and the formation of carbon-carbon bonds, which are fundamental steps in the synthesis of complex organic molecules.

Upstream product

• 5856-63-3 (2R)-2-aminobutan-1-ol 
• 1056016-65-9 2-chloro-6-[3-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine 

Relevant academic research and scientific papers

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1

Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC50: 220 nM), CDK5/p25 (IC50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1δ provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-β in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.